Galectin Therapeutics (GALT) Stock: Buy, Sell, or Hold?
GALT - Galectin Therapeutics Inc.
$3.37
-0.06 (-1.75%)
▼
5d:
-7.42%
30d:
-18.6%
90d:
-2.32%
HOLD
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 13, 2026
21d
Get Alerted When GALT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GALT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: GALT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: GALT is currently trading at $3.37, which is considered oversold relative to its 30-day fair value range of $3.60 to $3.96.
Technical Outlook: Technically, GALT is in a uptrend. Immediate support is located at $3.19, while resistance sits at $4.00.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+226.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GALT is in a uptrend. Immediate support is located at $3.19, while resistance sits at $4.00.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+226.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.60 -
$3.96
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
Protect Your Profits
Holding GALT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 226.4% below Wall St target ($11.00)
- NEUTRAL: Bottoming setup forming (45/100) — watch for confirmation
- CAUTION: 5-day price weakness (-7.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$3.60 -
$3.96
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.56
(16.6%)
Support & Resistance Levels
Support Level
$3.19
Resistance Level
$4.01
Current Trend
Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.65
Wall Street Target
$11.00
(+226.4%)
Share & Embed Analysis
Last updated: October 22, 2026 8:16 AM ET
Data refreshes hourly during market hours. Next update: 9:16 AM
Data refreshes hourly during market hours. Next update: 9:16 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GALT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 54 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 58 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 59 HOLD |
|
CLYM
Climb Bio Inc |
STRONG BUY
15 analysts |
$28 | 67 BUY |
Advanced GALT Option Strategies
Professional options setups generated by AI based on today's GALT price and gamma walls.
